Dr John Boyd Coates Iii, MD | |
195 Hospital Loop, Ste 5, Montpelier, VT 05602-8495 | |
(802) 229-5498 | |
(802) 229-2229 |
Full Name | Dr John Boyd Coates Iii |
---|---|
Gender | Male |
Speciality | Obstetrics & Gynecology |
Location | 195 Hospital Loop, Montpelier, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669425336 | NPI | - | NPPES |
1600 | Other | RAILROAD | |
0004798 | Medicaid | VT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 0420005278 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Boyd Coates Iii, MD 195 Hospital Loop, Ste 5, Montpelier, VT 05602-8495 Ph: (802) 229-5498 | Dr John Boyd Coates Iii, MD 195 Hospital Loop, Ste 5, Montpelier, VT 05602-8495 Ph: (802) 229-5498 |
News Archive
Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.
Cell migration, which is involved in wound healing, cancer and tumor growth, and embryonic growth and development, has been a topic of interest to mathematicians and biologists for decades.
The Supreme Court will hear arguments on Tuesday in a case that could decide whether generic drugmakers can be held liable for alleged flaws in the designs of their medications, even though federal law requires generic manufacturers to copy the brand drugmaker's design.
Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
› Verified 7 days ago